Research Letter: Molecule Enhances Skin Barrier, Reduces Retinoid Side Effects

A formulation containing Epicutis Skincare’s proprietary TSC molecule significantly reduced erythema and dryness caused by tretinoin, according to a research letter published in the Journal of Cosmetic Dermatology.

The study evaluated 60 patients who applied a combination of 0.5% Tetramethylhexadecenyl Succinoyl Cysteine (TSC) and 0.2% tretinoin to the face once daily for four weeks vs. patients using tretinoin alone served as controls. The patient population included individuals with Fitzpatrick skin types I–IV and no prior retinoid use within three months.

The primary outcomes were defined as changes in erythema and dryness, assessed using a four-point scale. After 4 weeks, the TSC-tretinoin group showed a 68% reduction in erythema and a 47% improvement in dryness compared to tretinoin alone. Patients also reported improved tolerance to tretinoin with reduced peeling and irritation.

The authors suggested that TSC’s anti-inflammatory properties and barrier-strengthening effects could account for the observed improvements. 

"Altogether, given these initial encouraging results, further study of TSC in a dose-dependent manner in a larger, controlled study is warranted," the study authors wrote.

Sources:

Epicutis press announcement, March 12, 2025. 

Perez E, et al. Journal of Cosmetic Dermatology. 2025. Doi:10.1111/jocd.70026